<DOC>
	<DOCNO>NCT00580970</DOCNO>
	<brief_summary>Lovastatin may protect late effect radiation therapy patient prostate cancer</brief_summary>
	<brief_title>Study Effectiveness Lovastatin Prevent Radiation-Induced Rectal Injury</brief_title>
	<detailed_description>Oral lovastatin give dose 20 mg/day even meal begin first day external beam radiation therapy ( external beam alone external beam follow brachytherapy ) first day brachytherapy ( brachytherapy alone brachytherapy follow external beam radiotherapy ) continue 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis adenocarcinoma prostate Planned treatment radiation therapy include external beam and/or brachytherapy curative intent ( total dose ≥60 Gy ) . A portion rectum must receive least 60 Gy . Age least 18 year Karnofsky Performance Status ( KPS ) ≥ 70 No history prior radiotherapy prostate rectum History prior malignancy , likely live least 4 year , acceptable . No evidence distant metastasis Patients may take HMGcoAreductase inhibitor , eligible , must able change lovastatin 20 mg/day , permission prescribe physician . Creatine kinase &lt; 5 time upper normal limit Sufficient renal function define calculated creatinine clearance ≥ 30ml/min transaminase &lt; 3 time upper normal limit Planned abdominoperineal resection radiotherapy Contraindication HMGcoAreductase inhibitor Major medical psychiatric illness , investigator 's opinion , would prevent completion treatment would interfere followup . Currently take inhibitor cytochrome P450 3A4 Active liver muscle disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>lovastatin</keyword>
	<keyword>rectal injury</keyword>
</DOC>